Table 4.
Proportions of patients randomized to GLP-1 RA treatment in CV outcome trials discontinuing study drug treatment, proportion of the follow-up period during which patients were exposed to the study drug, and proportions discontinuing due to adverse events.
| GLP-1 RA | Proportion of patients permanently discontinuing the study drug [%]a | Proportion of follow-up period during which the study drug was taken [%] | Proportion of patients discontinuing the study drug because of adverse events [%] | Trial/reference |
|---|---|---|---|---|
| Lixisenatide | 27.5 | 90.5 | 11.4 | ELIXA [95] |
| Liraglutide | n.p. | 84 | 9.5 | LEADER [96] |
| Once-weekly exenatide | 43.0 | 76 | 4.5c | EXSCEL [97] |
| Dulaglutide | 26.8 | 82.2 | 9.1 | REWIND [98] |
| Albiglutide | 24.5 | 87 | 8.6 | HARMONY Outcomes [99] |
| Semaglutide s.c. | 21.3 | 86.5 | 13.2 | SUSTAIN-6 [100] |
| Oral semaglutide | 15.3 | n.p.b | 11.6 | PIONEER-6 [101] |
n.p.: Not presented.
a
Not counting transient “drug holidays.”
b
75% received the study medication for more than 1 year (total follow-up of 15.3 months).
c
Counting only gastrointestinal adverse events. No CV outcome trial has been reported for exenatide b.i.d. (approved before these studies became mandatory).